Neuphoria holder Coastlands reports stake at 4.23%
Neuphoria Therapeutics Inc. shareholder group led by Coastlands Capital LP and Matthew D. Perry reports beneficial ownership of 228,594 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Neuphoria Therapeutics Inc. shareholder group led by Coastlands Capital LP and Matthew D. Perry reports beneficial ownership of 228,594 shares of common stock. Based on 5,404,551 shares outstanding as of May 14, 2026, this represents 4.23% of the company’s common stock.
The reporting persons hold no sole voting or dispositive power, but have shared voting and shared dispositive power over all 228,594 shares. They state that the securities were not acquired to change or influence control of Neuphoria Therapeutics. This Amendment No. 1 is described as an exit filing, as the group no longer beneficially owns more than 5% of any class of the issuer’s securities.
Key Figures
Key Terms
beneficial ownership financial
Schedule 13G regulatory
Rule 13d-3 regulatory
exit filing regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership level in Neuphoria Therapeutics (NEUP) is reported in this Schedule 13G/A?
Who are the reporting persons in the Neuphoria Therapeutics (NEUP) Schedule 13G/A?
Does the Coastlands group still own more than 5% of Neuphoria Therapeutics (NEUP)?
Is the Coastlands group seeking to influence control of Neuphoria Therapeutics (NEUP)?
AI-generated analysis. How Rhea-AI works. Not financial advice.